GPX4 and Miyoshi myopathy: As mentioned before, GPX4 inhibitor (RSL3 or ML162) was used in combination with bortezomib or lenalidomide in RPMI‐8226 MM cells, synergistically reducing the proliferation of MM cells and inducing ferroptosis [38].